Merck will have early-stage opportunities to help startups set up for future success in the pharmaceutical and life sciences fields.

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Germany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...

Pharmaceutical company Organon (NYSE:OGN) reported Q1 CY2025 results , but sales fell by 6.7% year on year to $1.51 billion.

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Sanofi plans to invest $20 billion in U.S.-based drug R&D and manufacturing over five years, creating jobs and boosting ...

The global market for brain metastasis treatment is poised for remarkable growth, projected to surge from approximately USD 4,282.22 million in 2025 to USD 8,823.13 million by 2035. This robust ...

The global brain tumor treatment market is undergoing a significant transformation, fueled by remarkable advancements in targeted therapy, immunotherapy, and personalized medicine. With projections ...

This cash-strapped company is shifting from its roots in cancer drug development to focus on cosmetic treatments.

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw158 ...

Mersana Therapeutics restructures to focus on breast cancer, extends cash runway to mid-2026, and reports promising Emi-Le progress in TNBC.